Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT04656457 Recruiting - Breast Cancer Clinical Trials

RESISTANCE VERSUS AEROBIC EXERCISES ON Breast Cancer Patients

Start date: December 12, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate which is more effective resistance or aerobic exercises on cancer related fatigue and immunity in breast cancer patients undergoing adjuvant chemotherapy.

NCT ID: NCT04656353 Recruiting - Breast Cancer Clinical Trials

An Impact Assessment of a Culturally Tailored Online Psychosocial Program for Chinese Immigrant Women With Breast Cancer

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of an online psychosocial self-help program for Chinese immigrant women with breast cancer, by comparing Chinese immigrant women who receive the online psychosocial program and those who do not receive the program. The investigators want to understand if this online psychosocial program is effective in helping Chinese immigrant women to feel more supported, understand that the distress is normal, engage in self-care activities, become aware of the community resources, feel more confident about returning to a normal life, and feel less distress overall as they return to life after treatment. This information will help us to better understand these Chinese immigrant women's needs and concerns and plan future growth of the program to meet their personal, cultural, and language needs.

NCT ID: NCT04654195 Recruiting - Clinical trials for Breast Cancer Patients

Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient

Start date: December 1, 2020
Phase:
Study type: Observational

polymorphisms of drug transporter genes may influence of Doxorubicin-Cyclophosphamide toxicity in breast cancer patients. the investigators want to evaluate the association between associations between genetic polymorphisms of ABCB1,SLC22A16 Genes and Toxicity of Doxorubicin and Cyclophosphamide Chemotherapy in Breast Cancer Patients treated by Doxorubicin-Cyclophosphamide regimen therapy

NCT ID: NCT04651452 Recruiting - Breast Cancer Clinical Trials

Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Aromatase inhibitors are a powerful medication for reducing the risk of recurrence and increasing survival in postmenopausal breast cancer patients. However, these medications can lead to intolerable side effects, poor medication adherence, and increased stress levels. This project's broad objective is to assess whether an intervention can improve medication adherence and reduce physical symptoms and stress in breast cancer patients prescribed aromatase inhibitors. Participants will be randomly assigned to a values affirmation or reflective journaling condition. Interventions will be writing-based, one essay per month for six months. Physical symptoms and perceived stress will be assessed at baseline, post-intervention (one month after the intervention), and follow-up (six months from the post-intervention assessment and seven months after the end of the intervention). Furthermore, an electronic pill bottle will continuously assess daily compliance so that medication adherence rates during the intervention, post-intervention, and follow-up can be calculated.

NCT ID: NCT04646759 Recruiting - Breast Cancer Clinical Trials

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Start date: October 14, 2020
Phase: Phase 3
Study type: Interventional

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and HER2 inhibitor pyrotinib have a synergistic effect. The preliminary analysis of our prospective shows that the efficacy is close to that of capecitabine combined with pyrotinib, and the adverse events are significantly improved compared with capecitabine combined with pyrotinib. Therefore, it is necessary to further carry out a head-to-head phase III randomized controlled clinical trial to study the efficacy and safety of fulvestrant combined with pyrotinib in the treatment of HR + / HER2 + advanced breast cancer.

NCT ID: NCT04646564 Recruiting - Clinical trials for Breast Cancer Metastatic

Radiotherapy for Extracranial Oligometastatic Breast Cancer

Start date: April 6, 2021
Phase: Phase 3
Study type: Interventional

More and more evidence suggests that local radiotherapy can improve the outcomes for patients with oligometastatic disease. The purpose of this study is to assess the impact of radiotherapy, compared with standard systemic therapy alone, on survival, local control and toxicities in patients with extracranial oligometastatic breast cancer. Eligible patients are randomized in a 1:2 ratio between the control arm (standard systemic therapy), and the WLRT arm (standard systemic therapy + radiotherapy). Randomization will be stratified by three factors: visceral metastasis (yes vs.no), number of metastases(≤2 vs. >2), hormone receptor(positive vs. negative). SBRT technique is preferred. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

NCT ID: NCT04645849 Recruiting - Breast Cancer Clinical Trials

Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer

C-PiACs
Start date: June 15, 2020
Phase:
Study type: Observational

This study aim to determine kinetic of post treatment recovery/variation of a panel of innate and adaptative immune system cells and molecules. The results should allow to determine the optimal post treatment immunomonitoring timing and panel to be used for future studies.

NCT ID: NCT04644068 Recruiting - Breast Cancer Clinical Trials

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

PETRA
Start date: November 12, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

NCT ID: NCT04641377 Recruiting - Clinical trials for Breast Cancer Female

Adaptations to Breast Cancer and Exercise Using Telehealth (ABRACE: Telehealth)

Start date: February 2021
Phase: N/A
Study type: Interventional

The aim of the present study is to determine the effects of 12 weeks of multicomponent training associated with a health education program carried out remotely, compared to a health education-only program, on psychological and physical outcomes of women in primary treatment for breast cancer. For that, 36 women will be randomized to a multicomponent training group carried out remotely associated with health education or health education group. The psychological and physical outcomes will be measured pre (week 0) and post-intervention (week 13) in both groups, always by the same investigator blinded in relation to the groups. The multicomponent training group will carry out an exercise program twice a week, and health education will also be carried out on one of the two days. In this group, the conversation on the topic of the week will take place during stretching. The sessions (on pre-established and non-consecutive days) will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be given by students of the Physical Education course, previously trained to perform the intervention. The order of the multicomponent training will be joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. For the participants of the health education group, also, once a week, a material with several topics related to the management of breast cancer diagnosis and physical activity will be sent by message. In addition, two days after this material is sent, a conversation will be held with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits. To analyze the outcomes collected, it will be used Generalized Estimating Equations (GEE) and the Bonferroni post-hoc test.

NCT ID: NCT04636710 Recruiting - Breast Cancer Clinical Trials

Refining Local-Regional Therapy for IBC

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This Feasibility study is trying to determine: - If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. - The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. - The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer - Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.